Evidence map›Paper›PMID 27747613›Full record

ReviewDrugs - real world outcomes2015

Impact of the 2013 French Pill Crisis on Women's Behaviour Regarding Contraception.

Magali Lemaitre, Glenn Lastennet, David Syr, Joseph Emmerich, Mahmoud Zureik

Open access · goldAbstract readReview
In one paragraph

Review in Drugs - real world outcomes, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Magali LemaitreNational Agency for the Safety of Medicines and Health Products (ANSM), 143-147 Boulevard Anatole France, 93285, Saint-Denis Cedex, France. magali.lemaitre@ansm.sante.fr.
Glenn LastennetNational Agency for the Safety of Medicines and Health Products (ANSM), 143-147 Boulevard Anatole France, 93285, Saint-Denis Cedex, France.
David SyrCeltipharm, Vannes, France.
Joseph EmmerichNational Agency for the Safety of Medicines and Health Products (ANSM), 143-147 Boulevard Anatole France, 93285, Saint-Denis Cedex, France.
Mahmoud ZureikNational Agency for the Safety of Medicines and Health Products (ANSM), 143-147 Boulevard Anatole France, 93285, Saint-Denis Cedex, France.
Agence Nationale de Sécurité du Médicament et des Produits de Santé · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextIn the last decade, several epidemiological studies have shown the increased risk of venous thromboembolism associated with third- and fourth-generation oral contraceptives (C3Gs and C4Gs) versus older combined first- and second-generation oral contraceptives (C1Gs and C2Gs). In France, in December 2012, a lawsuit filed against the National Agency for the Safety of Medicines and Health Products (ANSM) by a patient who had experienced a stroke, possibly due to the use of a C3G, triggered a national 'pill crisis'. Consequently, a 'crisis cell' was set up and pre-existing health recommendations were reinforced. The main aim of this study was to evaluate, in real time, the impact of the French health authorities' recommendations and communications on French women's behaviour regarding contraception.

methodsReal-time monthly sales data reported during 2013 were compared with monthly sales data reported in 2012. Analyses were stratified according to the type of contraceptive and age. An index corresponding to the number of months of contraception sold was developed to facilitate comparison of the different contraceptives despite their distinct features and to assess the overall trend of contraception.

resultsAfter a 2-year analysis (2013 versus 2012), a significant 45 % decrease (p < 0.0001) in C3G-4G sales was observed, compared with a significant increase of 30 % (p < 0.0001) in C1G-2G sales. The sharp increase in C1G-2G sales focused specifically on C2Gs with an oestrogen concentration below 20 µg. Moreover, a large (47 %) increase was reported in sales of intrauterine devices (p < 0.0001). Finally, taking all types of contraceptive sales into account, a slight decrease (1 %) in overall sales was identified.

conclusionThanks to an effective national communication plan, real-time monitoring of drug sales and favourable reactions from physicians and patients, French women changed their behaviour regarding contraception. However, this study was conducted over a short period following the crisis. A longitudinal analysis is required in order to assess any real long-term changes.

Identifiers

PMID27747613
PMCPMC4883198
OpenAlexW2018881892

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.